Blog
RSS FeedPosted by Michael Wonder on 22 Apr 2017
Institute for Clinical and Economic Review to review drugs for tardive dyskinesia in upcoming report
21 April 2017 - Report expected to include review of Ingrezza, recently approved, and Austedo, currently under FDA review; ICER's open ...
Posted by Michael Wonder on 12 Apr 2017
Pharmacy benefit management companies: do they create value in the US health care system?
12 April 2017 - Pharmacy benefit management companies perform functions in the US market-based healthcare system that may be performed by ...
Posted by Michael Wonder on 07 Apr 2017
Institute for Clinical and Economic Review's final report on treatments for rheumatoid arthritis finds evidence inadequate to distinguish overall benefits between newer agents and prices too high in relationship to the clinical value provided to patients
7 April 2017 - Final report and meeting summary reviews evidence on 11 targeted immune modulator drugs, including two currently under ...
Posted by Michael Wonder on 24 Mar 2017
ICER releases draft evidence report on crisaborole and dupilumab for atopic dermatitis
24 March 2017 - Public comment period open until 21 April. ...
Posted by Michael Wonder on 18 Mar 2017
Institute for Clinical and Economic Review to produce "New Evidence Update" Including updated value-based price benchmarks for PCSK9 inhibitors to treat high cholesterol
17 March 2017 - Update will incorporate new data on outcomes for patients with atherosclerotic cardiovascular disease released during the ...
Posted by Michael Wonder on 11 Mar 2017
Institute for Clinical and Economic Review releases revised report on targeted immune modulators for treatment of rheumatoid arthritis
10 March 2017 - Analyses of evidence on comparative effectiveness raise questions about current step therapy protocols, while net prices for ...
Posted by Michael Wonder on 07 Mar 2017
Institute for Clinical and Economic Review posts draft scoping document on treatments for ovarian cancer
6 March 2017 - Document will be open to public comment until 27 March 2017. ...
Posted by Michael Wonder on 06 Mar 2017
ICER's final report on disease-modifying therapies for multiple sclerosis finds most drugs are over-priced in relation to benefits for patients; highlights need for stakeholder collaboration to address system issues
6 March 2017 - Key policy recommendations call on manufacturers to cease price increases and payers to ease coverage restrictions and ...
Posted by Michael Wonder on 08 Feb 2017
Institute for Clinical and Economic Review to review treatments for ovarian cancer in upcoming report
8 February 2017 - Preliminary list of drugs to be reviewed includes rucaparib, niraparib and olaparib. ...
Posted by Michael Wonder on 01 Feb 2017
Institute for Clinical and Economic Review posts revised value assessment framework for public comment
1 February 2017 - Dr. Steven Pearson, ICER's President, will present proposed changes during 13 February webinar. ...
Posted by Michael Wonder on 27 Jan 2017
Institute for Clinical and Economic Review releases evidence report on disease-modifying therapies for multiple sclerosis, including daclizumab and ocrelizumab
26 January 2017 - Report finds alemtuzumab represents best long-term cost-effectiveness; prices for most drugs not well-aligned with added value ...
Posted by Michael Wonder on 22 Jan 2017
ICER releases draft evidence report on treatments for rheumatoid arthritis
20 January 2017 - Public comment period now open - comments accepted until 17 February. ...
Posted by Michael Wonder on 06 Dec 2016
ICER posts draft scoping document on treatments for osteoporosis
5 December 2016 - Document will be open to public comment until 23 December 2016. ...
Posted by Michael Wonder on 20 Oct 2016
Oncologists knock ICER's lung cancer cost-effectiveness review
20 October 2016 - Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for new medicines ...
Posted by Michael Wonder on 19 Oct 2016
ICER to review treatments for atopic dermatitis in upcoming report
19 October 2016 - The Institute for Clinical and Economic Review will develop a report assessing the comparative clinical effectiveness ...